Literature DB >> 18425081

Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection.

Daiki Okamura1, Masayuki Ohtsuka, Fumio Kimura, Hiroaki Shimizu, Hiroyuki Yoshidome, Atsushi Kato, Masaru Miyazaki.   

Abstract

Heterogeneous biological characteristics of hepatocellular carcinoma may be attributed to the cellular origin of the tumor. Patients with hepatocellular carcinoma probably derived from hepatic progenitor cells had early tumor recurrence after surgical resection or liver transplantation, suggesting that these tumors have aggressive characteristics. Ezrin, a member of the ERM (ezrin-radixin-moesin) cytoskeleton-associated protein family, is highly expressed in several types of human cancers and correlations between its immunoreactivity and patient outcome have been shown. In this study, ezrin expression, as well as cytokeratin19 and cytokeratin 7 expression, which are regarded as progenitor cell/ductular markers were immunohistochemically assessed in cases of hepatocellular carcinoma. In normal livers, ezrin expression was not found in any cell types, whereas cytokeratin 7 and cytokeratin 19 were exclusively stained in bile duct cells. In contrast, in livers with chronic hepatitis or cirrhosis, positive ezrin expression was observed in ductular reactions with strong intensity and intermediate hepatobiliary cells with various intensity. Of 77 cases of hepatocellular carcinoma, 28 (36%) had positive ezrin expression, 32 (42%) had cytokeratin 7 expression, and 11 (14%) had cytokeratin 19 expression. Ezrin expression in hepatocellular carcinoma was significantly associated with cytokeratin 19 expression, but not with cytokeratin 7 expression. Patients with ezrin-positive hepatocellular carcinoma had a significantly higher prevalence of elevated serum alpha-fetoprotein. Patients with immunohistochemical ezrin-positive hepatocellular carcinoma demonstrated significantly shorter recurrence-free and overall survival compared to patients with ezrin-negative hepatocellular carcinoma. Multivariate analysis revealed positive ezrin expression and multiple tumors to be independently associated with early recurrence in patients with hepatocellular carcinoma after curative surgical resection. These results suggested that hepatocellular carcinoma with ezrin expression might be at least partly derived from hepatic progenitor cells. Measurement of ezrin expression might be used to identify patients with an increased risk of early recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425081     DOI: 10.1038/modpathol.2008.59

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis.

Authors:  Ji Eun Kwon; Woo-Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2011-12-29

2.  The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome.

Authors:  Ming Wu; Ding-Yang Liu; Xian-Rui Yuan; Qing Liu; Xin-Jun Jiang; Dun Yuan; Jun Huang; Xue-Jun Li; Zhi-Quan Yang
Journal:  Med Oncol       Date:  2013-01-13       Impact factor: 3.064

3.  Ezrin expression and its phosphorylation in gastric carcinoma with lymphoid stroma and Epstein-Barr virus infection.

Authors:  Taro Tobo; Minako Hirahashi; Takashi Yao; Shinichi Aishima; Yoshinao Oda
Journal:  Mol Clin Oncol       Date:  2012-12-28

4.  Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma.

Authors:  Tanner L Bartholow; Anil V Parwani; Uma R Chandran; Michael J Becich
Journal:  BMC Clin Pathol       Date:  2011-01-14

5.  Expression of maspin and ezrin proteins in periocular Basal cell carcinoma.

Authors:  Mansooreh Bagheri; Masoomeh Eghtedari; Mandana Bagheri; Bita Geramizadeh; Mohammadreza Talebnejad
Journal:  Dermatol Res Pract       Date:  2014-12-15

6.  The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma.

Authors:  Yangkyu Lee; Hyunjin Park; Hyejung Lee; Jai Young Cho; Yoo-Seok Yoon; Young-Rok Choi; Ho-Seong Han; Eun Sun Jang; Jin-Wook Kim; Sook-Hyang Jeong; Soomin Ahn; Haeryoung Kim
Journal:  J Pathol Transl Med       Date:  2017-11-24

7.  Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.

Authors:  Yi-Chieh Yang; Ming-Hsien Chien; Tsung-Ching Lai; Min-Che Tung; Yi-Hua Jan; Wei-Ming Chang; Shih-Ming Jung; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  J Biomed Sci       Date:  2021-04-22       Impact factor: 8.410

8.  Z-Guggulsterone Is a Potential Lead Molecule of Dawa-ul-Kurkum against Hepatocellular Carcinoma.

Authors:  Meenakshi Gupta; Shaikh Maryam Ghufran; Tasneem Kausar; Rafat Ali; Subhrajit Biswas; Shahid M Nayeem; Romana Ishrat; Sher Ali; Ajaz Ahmad; Irfan A Rather; Maryam Sarwat
Journal:  Molecules       Date:  2022-08-11       Impact factor: 4.927

9.  12-O-Tetradecanoylphorbol-13-Acetate Induces Up-Regulated Transcription of Variant 1 but Not Variant 2 of VIL2 in Esophageal Squamous Cell Carcinoma Cells via ERK1/2/AP-1/Sp1 Signaling.

Authors:  Xiao-Dan Zhang; Jian-Jun Xie; Lian-Di Liao; Lin Long; Yang-Min Xie; En-Min Li; Li-Yan Xu
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma.

Authors:  Gi Jeong Kim; Hyunki Kim; Young Nyun Park
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.